PCM
UTHR icon

Price Capital Management’s United Therapeutics UTHR Stock Holding History

Price Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-6,086
Closed -$689K – 152
2018
Q2 		$689K Buy
+6,086
New +$669K 0.34% 121

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Price Capital Management's UTHR Position: Q3 2018 in Review

Price Capital Management sold out of United Therapeutics (UTHR) in Q3 2018, closing a stake of 6,086 shares — an estimated $689K sold.

Price Capital Management first reported a position in UTHR in Q2 2018 and held it in 1 quarter. The position peaked at $689K in Q2 2018. 367 funds tracked by Wall St. Rank hold UTHR as of Q3 2018.

  • Price Capital Management reported no remaining United Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Price Capital Management sold 6,086 United Therapeutics shares in Q3 2018, an estimated $689K.
  • Price Capital Management first reported a position in United Therapeutics in Q2 2018 and held it in 1 quarter.
  • Price Capital Management's United Therapeutics position peaked at $689K in Q2 2018.
  • 367 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2018.

Based on Price Capital Management's 13F filing for Q3 2018, filed 29 Oct 2018.